NCT05633654: Phase 3: (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC
First Posted 2022-11-21 Trial status Recruiting Sponsor Gilead Sciences Abstract Presentation Peer-reviewed journal publication Press Release FDA NCCN NCT05633654: Phase 3: (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Hav
Dec 1, 2022